Találati lista | Tudóstér

001-es BibID:	BIBFORM048273
Első szerző:	Meskó Bertalan (kutatóorvos)
Cím:	Peripheral blood derived gene panels predict response to infliximab in rheumatoid arthritis and Crohn's disease / Bertalan Mesko, Szilard Poliska, Andrea Váncsa, Zoltan Szekanecz, Karoly Palatka, Zsolt Hollo, Attila Horvath, Laszlo Steiner, Gabor Zahuczky, Janos Podani, Laszlo Nagy
Dátum:	2013
ISSN:	1756-994X
Megjegyzések:	Biological therapies have been introduced for the treatment of chronic inflammatory diseases including rheumatoid arthritis (RA) and Crohn's disease (CD). The efficacy of biologics differs from patient to patient. Moreover these therapies are rather expensive, therefore treatment of primary non-responders should be avoided.METHOD:We addressed this issue by combining gene expression profiling and biostatistical approaches. We performed peripheral blood global gene expression profiling in order to filter the genome for target genes in cohorts of 20 CD and 19 RA patients. Then RT-quantitative PCR validation was performed, followed by multivariate analyses of genes in independent cohorts of 20 CD and 15 RA patients, in order to identify sets ofinterrelated genes that can separate responders from non-responders to the humanized chimeric anti-TNFalpha antibody infliximab at baseline.RESULTS:Gene panels separating responders from non-responders were identified using leave-one-out cross-validation test, and a pool of genes that should be tested on larger cohorts was created in both conditions.CONCLUSIONS:Our data show that peripheral blood gene expression profiles are suitable for determining gene panels with high discriminatory power to differentiate responders from non-responders in infliximab therapy at baseline in CD and RA, which could be cross-validated successfully. Biostatistical analysis of peripheral blood gene expression data leads to the identification of gene panels that can help predict responsiveness of therapy and support the clinical decision-making process.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban RA patient Crohn's disease chronic inflammatory diseases
Megjelenés:	Genome Medicine. - 5 : 6 (2013), p. 59-69. -
További szerzők:	Póliska Szilárd (1978-) (biológus) Váncsa Andrea (1972-) (orvos) Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Palatka Károly (1961-) (belgyógyász, gasztroenterológus) Holló Zsolt Horváth Attila (1988-) (programtervező informatikus) Steiner László Zahuczky Gábor (1975-) (molekuláris biológus, biokémikus, vegyész) Podani János Nagy László (1966-) (molekuláris sejtbiológus, biokémikus)
Pályázati támogatás:	NK72730 OTKA K100196 OTKA REGPOT-2008-1-01/MOLMEDREX/229920 FP7 TÁMOP-4.2.2/08/1 TÁMOP ETT 294-07 Egyéb K 105073 OTKA TÁMOP-4.2.2.A-11/1/KONV-2012-0031 TÁMOP
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM037784
Első szerző:	Meskó Bertalan (kutatóorvos)
Cím:	The triad of success in personalised medicine : pharmacogenomics, biotechnology and regulatory issues from a Central European perspective / Mesko Bertalan; Zahuczky Gabor; Nagy Laszlo
Dátum:	2012
ISSN:	1871-6784
Megjegyzések:	The population of the world has recently passed the 7 billion milestone and as the cost of human genome sequencing is rapidly declining, sequence data of billions of people should be accessible much sooner than anyone would have predicted 10years ago. This will form the basis of personalised medicine. However it is still not clear, even in principle, whether these data, combined with data of the expression of one's genome in various cells and tissues relevant to different diseases, could be used effectively in clinical medicine and healthcare, or in predicting responses to different therapies. Therefore this is an important issue which needs to be addressed before more resources are wasted on less than informative studies and surveys simply because technologies exist. As a typical example, we have selected and summarise here key studies from the biomedical literature that focus on gene expression profiling of the response to biologic therapies in peripheral blood and biopsy samples in autoimmune diseases such as rheumatoid arthritis, spondylarthropathy, inflammatory bowel diseases and psoriasis. We also present the state of the biotechnology market from a European perspective, discuss how spin-offs leverage the power of genomic technologies and describe how they might contribute to personalised medicine. As ethical, legal and social issues are essential in the area of genomics, we analysed these aspects and present here the European situation with a special focus on Hungary. We propose that the synergy of these three issues: pharmacogenomics, biotechnology and regulatory issues should be considered a triad necessary to succeed in personalised medicine.
Tárgyszavak:	Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:	New Biotechnology. - 29 : 6 (2012), p. 741-750. -
További szerzők:	Zahuczky Gábor (1975-) (molekuláris biológus, biokémikus, vegyész) Nagy László (1966-) (molekuláris sejtbiológus, biokémikus)
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon: